Torrent Pharmaceuticals submits ANDA for Vericiguat
The submission of an ANDA for Vericiguat by Torrent Pharmaceuticals introduces a potential generic competitor in the heart failure market. This could disrupt pricing and market share for existing therapies, necessitating strategic adjustments from incumbent companies.
Company
Torrent Pharmaceuticals
Asset
Vericiguat
Indication
Cardiology / Heart Failure
Status
Approved
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Strategic implication
The submission of an ANDA for Vericiguat by Torrent Pharmaceuticals introduces a potential generic competitor in the heart failure market. This could disrupt pricing and market share for existing therapies, necessitating strategic adjustments from incumbent companies.
Why it matters
The submission of an ANDA for Vericiguat by Torrent Pharmaceuticals introduces a potential generic competitor in the heart failure market. This could disrupt pricing and market share for existing therapies, necessitating strategic adjustments from incumbent companies.
What changed
Regulatory Approval
Analysis
Torrent Pharmaceuticals has submitted an Abbreviated New Drug Application (ANDA) for Vericiguat.
The submission of an ANDA for Vericiguat by Torrent Pharmaceuticals introduces a potential generic competitor in the heart failure market. This could disrupt pricing and market share for existing therapies, necessitating strategic adjustments from incumbent companies.
Monitor the FDA's review process and potential approval timeline for ANDA220221.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.